Care Access

What Care Access does

Care Access is a global, decentralized clinical research company operating a hybrid network of more than 150 permanent research sites and a fleet of 158+ mobile research vehicles that conducts Phase I-IV trials for pharmaceutical and biotech sponsors across 14 therapeutic areas. The company serves 14 of the top 20 biopharmaceutical companies — including Eli Lilly, AbbVie, Pfizer, Moderna, Sanofi, Janssen, Takeda, BMS, AstraZeneca, Novartis, and Novo Nordisk — and supports more than 300 active trials, with a stated mission of reaching historically underserved and diverse populations through community-based engagement and 1,000+ annual local events.

Its service stack is organized around three pillars: (1) site operations, anchored by Sites On Demand and Mobile Sites On Demand that allow rapid physical deployment of trial infrastructure; (2) Central Clinical Services (CCS) and Site Staffing, which provide centralized recruitment, enrollment, follow-up, study start-up/close-out, and specialized clinical research professionals to sponsor or third-party sites; and (3) the Future of Medicine consumer-facing program, which offers no-cost community health screenings, optional subscription add-on laboratory tests, and a referral program (Care for Friends). Technology layers include the StudyTeam site operations platform and "Peter The Protocol Reader," an AI tool for interpreting clinical trial protocols, alongside AI-assisted phone, text, and electronic communications for scheduling, reminders, and intake.

Care Access generates revenue primarily through professional-services contracts with pharma and biotech sponsors for trial execution, with site staffing and CCS representing additional service revenue lines. Consumer-side revenue is limited to optional paid add-on testing services; the screening program itself is offered at no cost and does not require insurance. The company is privately held (Care Access Research LLC, Delaware) and has expanded internationally via the acquisitions of IBPClin (Rio de Janeiro, 2022) and CEMEC (São Bernardo do Campo, 2025) in Brazil, with additional operations in the United States, Canada (Nova Scotia), Poland, and New Zealand.

Name

Care Access

Legal name

Care Access Research LLC

Website

https://careaccess.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Care Access is a global decentralized clinical research company operating 150+ permanent sites and 158+ mobile research vehicles to run Phase I-IV trials for 14 of the top 20 biopharma sponsors, while delivering community health screenings to historically underserved populations.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Clinical Research Site Services)

NAICS

Home Health Care Services (62161)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH)

Keywords

• Decentralized clinical trials
• Contract research organization
• Clinical research site services
• Site staffing solutions
• Community health screening

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices13 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Site Services: Care Access operates as a CRO providing clinical trial execution services to pharmaceutical and biotech sponsors. Revenue is generated through service contracts for conducting trials at their global network of research sites, including patient recruitment, screening, enrollment, and data collection services
2. Site Staffing Solutions: Provides specialized clinical research staffing services to research sites, including clinical research coordinators, sub-investigators, nurses, pharmacists, and other specialized roles. Services are provided to sites supporting sponsors' trials
3. Central Clinical Services: Centralized operational support services that reduce site administrative burden. Includes recruitment and screening support, enrollment visit management, follow-up services, and study start-up/close-out support. Priced relative to CTA spend with reported 10-20% cost savings
4. Community Health Screening: Health screening services offered to participants at no cost, with optional add-on testing services available for purchase. Generates opportunities for clinical trial recruitment

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Care Access is a global clinical research company operating as a contract research organization (CRO) for pharmaceutical and biotech sponsors. It runs decentralized clinical trials through a hybrid model combining 150+ permanent research sites with a fleet of 158+ mobile research vehicles, supplemented by centralized support services (recruitment, enrollment, follow-up, study start-up/close-out) and specialized site-staffing solutions. A free Future of Medicine program and community health screenings generate and engage diverse trial participants.

Product overview

Care Access operates as a global clinical research company offering a comprehensive platform for decentralized and community-based clinical trials. The core offering is the Future of Medicine Program, which combines health screenings, laboratory testing, and research study participation opportunities. Supporting this are three main service pillars: (1) a global network of over 150 permanent research site locations plus Mobile Sites On Demand™ that bring trials directly to underserved communities via a fleet of mobile research vehicles; (2) Central Clinical Services (CCS) providing recruitment, enrollment, follow-up, and study start-up/close-out support, and Site Staffing offering clinical research professionals; and (3) community health screening programs including Heart & Kidney Health Screening and the Lp(a) Screening Program. Technology offerings include StudyTeam Platform and Peter The Protocol Reader. Care Access has expanded internationally through acquisitions of IBPClin and CEMEC in Brazil, and operates across North America, Canada, Poland, Brazil, and New Zealand. The company serves 14 of the top 20 biopharmaceutical companies across 14 therapeutic areas including neurology, gastroenterology, dermatology, cardiology, and respiratory.

Differentiator

Problem solved

Functional benefit

Products and services

• Future of Medicine Program Consumer-facing program that combines health screenings, laboratory testing, and access to clinical research opportunities to help individuals learn about their health and participate in medical research.
• Sites On Demand On-demand physical-space expansion service for sponsors that delivers temporary or permanent research site infrastructure to support clinical trials in specific communities.
• Mobile Sites On Demand Mobile version of the Sites On Demand model that uses the company's fleet of mobile research vehicles and traveling clinical staff to bring clinical trial operations directly to hard-to-reach, underrepresented communities.
• Central Clinical Services (CCS) Centralized operational support service covering recruitment and screening, enrollment and treatment visits, ongoing follow-up, and study start-up/close-out activities for sponsor trials; reported to reduce CTA spend by 10–20% and complete visits ~6 days faster.
• Site Staffing Staff augmentation offering providing specialized research professionals—clinical research coordinators, sub-investigators, patient educators, nurses, pharmacists, and other roles—to support trial execution at sponsor sites.
• Patient Education Program Community-facing program in which Patient Educators deliver culturally sensitive education, build trust in local communities, support trial enrollment at community events, and help patients make informed decisions about participation.
• Patient Resource Partner Program Program that places Patient Resource Partners alongside participants to reduce barriers to care, conduct needs assessments, enroll patients in financial-assistance programs, and provide ongoing guidance through the trial journey to improve engagement and retention.
• Care for Friends Referral Program Referral program allowing community Champions to earn $25 USD per qualified referral (up to 400 referrals or $10,000 maximum) for referring new participants to Care Access health screening programs or studies.
• Community Health Screening Health screening service delivered directly to communities at local events such as churches, community centers, and other neighborhood locations to expand access to preventive care and identify potential clinical-trial participants.
• Heart & Kidney Health Screening Featured cardiometabolic screening program focused on cardiovascular and kidney health, offered at multiple U.S. and international locations to identify at-risk individuals and connect them with relevant clinical research opportunities.
• Lp(a) Screening Program Cardiovascular research screening program providing free lipoprotein(a) [Lp(a)] testing and connecting identified participants with clinical trials investigating treatments for elevated Lp(a).
• StudyTeam Platform Site technology platform for managing clinical trial operations, patient enrollment, and research-site coordination across Care Access's network.
• Peter The Protocol Reader AI-powered clinical trial protocol reader that interprets and helps navigate trial protocols to support faster study start-up and consistent execution.

Named customers18 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, regional and minor.

• Walmart Healthcare Research InstitutecoreStrategic or Co-development Partner · 22 January 2026Care Access and Walmart Healthcare Research Institute collaborating to open clinical research sites in three Walmart Health locations in Texas and Georgia, plus one rural Walmart store. Care Access will provide clinical research opportunities and advanced health screenings at these locations.
• Association of Black Cardiologists (ABC)coreStrategic or Co-development Partner · 19 November 2025Partnership to expand heart health screenings and research opportunities to more communities by combining Care Access's global community health screening program with ABC's trusted network of physicians, health professionals, and community advocates.
• Centro Multidisciplinar de Estudos Clínicos (CEMEC)coreOEM/ Whitelabel/ Licensing Partner · 10 March 2025Acquisition of CEMEC in São Bernardo do Campo, Brazil. CEMEC has run over 100 trials across 18 therapeutic areas in outpatient and hospital settings, covering Phase II, III, and IV clinical studies. Second major expansion in Brazil following IBPClin acquisition.
• U.S. Department of Health and Human Services (HHS)coreStrategic or Co-development Partner · 26 August 2024Strategic partnership to enhance the nation's pandemic preparedness, enabling rapid response capabilities during public health emergencies like COVID-19.
• Aotearoa Clinical Trials (New Zealand)regionalStrategic or Co-development Partner · 1 January 2024Partnership to expand availability of clinical research in New Zealand, bringing clinical trials to diverse and underrepresented communities throughout the country.
• Instituto Brasil de Pesquisa Clínica (IBPClin)coreOEM/ Whitelabel/ Licensing Partner · 29 June 2022Acquisition of IBPClin in Rio de Janeiro, Brazil as initial expansion into Latin America. IBPClin operates as a Care Access company bringing decentralized trial model to underserved communities in the region.
• Eli Lilly and Company - Oncology Diversity PartnershipcoreStrategic or Co-development Partner · 28 September 2021Expanded partnership to broaden patient access to clinical trials and increase representation of minority group members including African American, Hispanic, and LatinX populations in oncology trials.
• AstraZenecacoreStrategic or Co-development Partner · 26 January 2021Collaboration to accelerate Phase III clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody combination for potential prevention of COVID-19.
• Morgan CARES / Morgan State UniversitycoreStrategic or Co-development PartnerCommunity-Aligned Research Solutions partnership to eliminate health disparities and improve healthcare access. Morgan CARES serves as principal collaborator alongside Johns Hopkins. Working on 'Research Empowered Community' program to create Community Councils at Care Access sites.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerIMPACT (Improving Participation Among diverse populations in Cardiovascular clinical Trials) center led by Dr. Erin Michos, part of the American Heart Association's Strategically-Focused Research Network on Diversity in Clinical Trials. Care Access and BRIDGE Initiative providing financial support and in-kind services.
• American Heart Association - BRIDGE InitiativecoreStrategic or Co-development PartnerBRIDGE (Bringing Representation, Inclusion & Diversity to Global Enrollment) Initiative supporting diversity in clinical trial research. Care Access contributed $4 million to add sixth research center to AHA's $24 million research network on diversity in clinical trials.
• Decentralized Trials & Research Alliance (DTRA)minorGTM or Marketing PartnerMember and active participant in DTRA Annual Meeting; supporting industry-wide adoption of decentralized trial approaches.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the largest global CRO with broad Phase I-IV capabilities, large DCT investments, and entrenched relationships with the same top-20 biopharma clients as Care Access. It is the principal broad incumbent competing for decentralized trial mandates.
• ICON plc: ICON is a top-3 global CRO offering full Phase I-IV services plus decentralized and hybrid trial solutions following its PRA Health Sciences combination. Competes for the same enterprise biopharma sponsors.
• Labcorp (Covance Drug Development): Labcorp's Covance business is a leading global CRO with decentralized trial capabilities and central laboratory services. It overlaps with Care Access in serving top biopharma sponsors across multiple therapeutic areas.
• Syneos Health: Syneos Health is a biopharmaceutical solutions organization offering clinical development and commercialization services, including decentralized and hybrid trial capabilities. Competes for similar biopharma sponsor work as Care Access.
• Parexel International: Parexel is a global CRO with full-service Phase I-IV capabilities and an emerging decentralized trial offering. Competes for the same top biopharma sponsors and therapeutic areas served by Care Access.

Direct peers

• Science 37: Science 37 is a DCT-native company offering a decentralized clinical trial operating system and site network, directly competing with Care Access's decentralized and hybrid model for sponsor contracts focused on remote trial delivery.
• Medpace: Medpace is a mid-to-large clinical CRO focused on Phase I-IV trials across multiple therapeutic areas, particularly strong in oncology, cardiology, and metabolic disease. Competes for many of the same therapeutic-area trials as Care Access.
• Velocity Clinical Research: Velocity is a site-management organization with a large multi-site network in the US, directly comparable to Care Access's site business and competing for sponsor site-service contracts across similar therapeutic areas.
• Elligo Health Research: Elligo operates a decentralized research model that brings trials into community physician practices, very similar in approach to Care Access's community and mobile-based model for reaching underrepresented patients.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO focused on complex Phase II-IV trials in CNS, cardiometabolic, and rare disease therapeutic areas, overlapping with several of Care Access's 14 served therapeutic areas.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Care_Access_
• Facebookfacebook.com/CareAccessHealth
• LinkedInlinkedin.com/company/careaccess
• Instagraminstagram.com/careaccesshealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Care Access